Due to its central role in tumor processes, STAT3 has been considered a potential anticancer target since its first description as an oncogene in 1998 and has led to the evaluation of STAT3 inhibitors for their antitumor activity in vitro and in vivo using experimental tumor models [11]. The gene discussed is STAT3; the disease is neoplasm.